P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, ...

The pharmaceutical industry has bounced back in 2024. After barely growing by 0.5% in 2023, the sector has made a solid ...

From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

The data analytics and consulting company valued the market at $8.4 billion in 2021. The forecasted 7.4% compound annual ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

A groundbreaking antipsychotic, a powerful new antibiotic, and a vaccine-like prophylactic for HIV are some of the most ...

BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely ...

schizophrenia treatment market is expected to expand globally by enhancing existing treatments and improving patient care.

Bristol Myers Squibb’s Cobenfy is the first treatment in seven decades that does not modulate dopaminergic or serotonergic ...

Foods must also limit sodium and saturated fat at levels that depend on the type of product, the FDA said.The change banishes foods such as sugary cereals, highly sweetened yogurts, white bread ...